Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
| Daunorubicin | Cerubidine | Rubidomycin|daunomycin hydrochloride|rubomycin C|Acetyladriamycin | Chemotherapy - Anthracycline 13 | Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov). |
| Dexamethasone | Adexone | Desametasone | ||
| Hydrocortisone | Cortisol | |||
| Pegaspargase | Oncaspar | PEG-asparaginase|PEG-ASP | Oncaspar (pegaspargase) is a pegylated version of L-asparaginase, which converts L-asparagine to ammonia and L-aspartic acid, reducing available asparagine resulting in decreased protein synthesis, inhibition of tumor cell proliferation, and increased apoptosis (NCI Drug Dictionary). | |
| Thioguanine | Lanvis | 2-Amino 6MP | ||
| Vincristine sulfate liposome | Marqibo | VSL | Marqibo (vincristine sulfate liposome) is a liposomal formulation of vincristine with improved bioavailability (PMID: 23212117). Marqibo (vincristine sulfate liposome) is FDA-approved for Philadelphia chromosome (BCR-ABL1)-negative acute lymphoblastic leukemia (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02828358 | Phase II | Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | Completed | USA | CAN | AUS | 1 |